Celltrion
Update in progress068270.KS (KSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Celltrion, Inc. is a biopharmaceutical company that develops, manufactures, and markets biosimilars and related medicines. Its portfolio includes Remsima, Truxima, Herzuma, Vegzelma, and other biosimilars, plus products for asthma, diabetic eye disease, cancer, and autoimmune diseases. It also has late-stage candidates such as CT-P44, CT-P51, CT-P53, CT-P55, and CT-G20. The company sells in about 100 countries and is based in Incheon, South Korea, founded in 2002.
Company score
- Sentiment
- 3.23
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.03
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 1.46
- Governance
- 0.85
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.60
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 1.92
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketKSE (KSC)
- LocationSouth Korea
- CEOMr. Woo-Sung Kee
- Founded2002
- Employees2,956
- Websitewww.celltrion.com
Identifiers
- ISINKR7068270008